← Back to Screener
Amarin Corp Plc (AMRN)
Price$14.62
Favorite Metrics
Price vs S&P 500 (26W)-26.57%
Price vs S&P 500 (4W)-6.11%
Market Capitalization$311.74M
All Metrics
P/CF (Annual)46.34x
Book Value / Share (Quarterly)$22.07
P/TBV (Annual)0.63x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-16.67%
Cash Flow / Share (Quarterly)$0.32
Price vs S&P 500 (YTD)3.21%
Gross Margin (TTM)60.17%
Net Profit Margin (TTM)-18.94%
EPS (TTM)$-1.46
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-1.46
Revenue Growth (5Y)-19.04%
EPS (Annual)$-0.09
ROI (Annual)-8.45%
Gross Margin (Annual)56.57%
Net Profit Margin (5Y Avg)-20.14%
Cash / Share (Quarterly)$14.54
Revenue Growth QoQ (YoY)-21.00%
ROA (Last FY)-5.78%
Revenue Growth TTM (YoY)-28.13%
EBITD / Share (TTM)$-0.21
ROE (5Y Avg)-10.54%
Operating Margin (TTM)-23.82%
Cash Flow / Share (Annual)$0.32
P/B Ratio0.68x
P/B Ratio (Quarterly)0.61x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.08x
Net Interest Coverage (TTM)-13.91x
ROA (TTM)-5.84%
EV / EBITDA (TTM)16.57x
EPS Incl Extra (Annual)$-0.09
Current Ratio (Annual)3.34x
Quick Ratio (Quarterly)2.21x
3-Month Avg Trading Volume0.08M
52-Week Price Return60.04%
EV / Free Cash Flow (Annual)26.32x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$21.43
P/S Ratio (Annual)1.46x
Asset Turnover (Annual)0.32x
52-Week High$20.90
Operating Margin (5Y Avg)-22.51%
EPS Excl Extra (Annual)$-0.09
Tangible BV CAGR (5Y)-6.19%
26-Week Price Return-17.83%
Quick Ratio (Annual)2.21x
13-Week Price Return-0.20%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.34x
Enterprise Value$177.084
Revenue / Share Growth (5Y)-20.38%
Asset Turnover (TTM)0.25x
Book Value / Share Growth (5Y)69.05%
Revenue / Employee (Annual)$3
Inventory Turnover (Annual)0.51x
Pretax Margin (Annual)-16.87%
Cash / Share (Annual)$14.54
3-Month Return Std Dev48.42%
Gross Margin (5Y Avg)64.93%
Net Income / Employee (TTM)$-0
ROE (Last FY)-8.45%
Net Interest Coverage (Annual)-14.99x
EPS Basic Excl Extra (Annual)$-0.09
P/FCF (TTM)9.78x
Receivables Turnover (TTM)1.32x
EV / Free Cash Flow (TTM)26.32x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.46
Receivables Turnover (Annual)1.72x
ROI (TTM)-8.36%
P/S Ratio (TTM)1.90x
Pretax Margin (5Y Avg)-18.86%
Revenue / Share (Annual)$0.51
Tangible BV / Share (Annual)$21.43
Forward P/E487.33x
Price vs S&P 500 (52W)24.95%
Year-to-Date Return7.34%
5-Day Price Return3.24%
EPS Normalized (Annual)$-0.09
ROA (5Y Avg)-7.22%
Net Profit Margin (Annual)-18.16%
Month-to-Date Return3.60%
Cash Flow / Share (TTM)$-0.12
EBITD / Share (Annual)$-0.11
Operating Margin (Annual)-23.48%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)46.34x
ROI (5Y Avg)-10.54%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.46
P/TBV (Quarterly)0.63x
P/B Ratio (Annual)0.61x
Inventory Turnover (TTM)0.51x
Pretax Margin (TTM)-17.03%
Book Value / Share (Annual)$22.07
Price vs S&P 500 (13W)-3.07%
Beta0.87x
P/FCF (Annual)46.34x
Revenue / Share (TTM)$0.39
ROE (TTM)-8.36%
52-Week Low$8.84
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AMRNAmarin Corp Plc | 1.90x | -28.13% | 60.17% | — | $14.62 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Amarin Corporation PLC is a pharmaceutical company specializing in cardiovascular health therapeutics. The company commercializes Vascepa, a treatment designed to reduce cardiovascular risk and prevent CV-related mortality. Amarin derives the majority of its revenue from the United States market.